Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/106531
Título: Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
Autores/as: Stuckey, Ruth
López-Rodríguez, Juan Francisco
Sánchez Sosa, José Santiago 
Segura Díaz, Adrian 
Sánchez-Farías, Nuria
Bilbao Sieyro, Cristina 
Gómez Casares, María Teresa 
Clasificación UNESCO: 32 Ciencias médicas
320101 Oncología
Palabras clave: BCR-ABL positive
Biomarkers
Chronic
Duration of therapy
Leukemia, et al.
Fecha de publicación: 2020
Publicación seriada: World Journal of Clinical Oncology 
Resumen: Clinical trials have demonstrated that some patients with chronic myeloid leukemia (CML) treated for several years with tyrosine kinase inhibitors (TKIs) who have maintained a molecular response can successfully discontinue treatment without relapsing. Treatment free remission (TFR) can be reached by approximately 50% of patients who discontinue. Despite having similar levels of deep molecular response and an identical duration of treatment, the factors that influence the successful discontinuation of CML patients remain to be determined. In this review we will explore the factors identified to date that can help predict whether a patient will successfully achieve TFR. We will also discuss the need for the identification of predictive biomarkers associated with a high probability of achieving TFR for the future personalized identification of patients who are suitable for the discontinuation of TKI treatment.
URI: http://hdl.handle.net/10553/106531
ISSN: 2218-4333
DOI: 10.5306/wjco.v11.i12.996
Fuente: World Journal of Clinical Oncology [ISSN 2218-4333], v. 11 (12), p. 996-1007 (Diciembre 2020)
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.